Back to Stakeholders
Categories

1 domain / 2 areas / 1 specialization

Peter Thiel

Data updated

Silicon Valley, California, United States

Peter Thiel is a partner at Founders Fund, a Silicon Valley venture capital firm, and is publicly associated with investing through that platform. Public company materials also identify him as a named investor in atai Life Sciences financing rounds.

In the psychedelic ecosystem, Thiel is relevant primarily through atai Life Sciences, a clinical-stage biotech company developing psychedelic and non-psychedelic compounds for mental health indications. atai’s financing announcements describe him as a co-lead investor in the company’s Series C round and as one of the investors in a later convertible note financing.

Investor Context

Angel Investors

Investment Context

This stakeholder is listed as an Angel Investor within Angel Investors. Its public geography context is global. Public stage signals include Series A/B and Growth / Late Stage. Public focus areas include Drug Development.

Public Portfolio Examples

Peter Thiel’s public psychedelic relevance is centered on atai Life Sciences, where he appears in financing announcements tied to drug development for mental health. The record fits a growth-oriented investor profile with exposure to biotech and company-building through Founders Fund, rather than a dedicated psychedelic-only mandate.

Investor Type

Angel Investor

Geographic Scope

Global

Psychedelic Focus

Explicit Psychedelic Focus

Engagement

Monitoring-Only

Investment Stage Focus

Series A/BGrowth / Late Stage

Investment Focus Areas

Drug Development

Investment Orientation

Engagement Status

Monitoring-Only

Investor Type

Angel Investor

Investment Website

Recorded Investments

atai Life Sciences

Nov 23, 2020

Series C financing (co-led) - $125m financing round

Date uses press release date.

ATAI closes $125m Series C financing round

Convertible note financing - $24 million

Peter Thiel is named among the investors participating in the note financing.

ATAI Life Sciences announces close of $24 million convertible note financing round and welcomes Jason Camm of Thiel Capital to Board of Directors

Quick Facts

HQ
Silicon Valley, California, United States
Website
Visit